Showing results (731-740 of 863) with videos related to

Sort By:
Pageof 87
Cancers|August 7, 2021
Effects of and Lessons Learned from an Internet-Based Physical Activity Support Program (with and without Physiotherapist Telephone Counselling) on Physical Activity Levels of Breast and Prostate Cancer Survivors: The PABLO Randomized Controlled TrialH J van de Wiel, M M Stuiver, A M May, et al.
Nature Genetics|May 5, 2022
Prioritization of autoimmune disease-associated genetic variants that perturb regulatory element activity in T cellsKousuke Mouri, Michael H Guo, Carl G de Boer, et al.
Analytical Chemistry|July 14, 2025
Robust Automated Separation of Circulating Tumor Cells and Cancer-Associated Fibroblasts for Enhanced Liquid Biopsy in Breast CancerHyeong Jung Woo, Paul N Rademacher, Hyun Young Shin, et al.
Cancers|April 12, 2022
Cell-Free DNA at Diagnosis for Stage IV Non-Small Cell Lung Cancer: Costs, Time to Diagnosis and Clinical RelevanceSimone N Koole, Daan C L Vessies, Milou M F Schuurbiers, et al.
Neurology|July 10, 2024
Predicting Cognitive Decline in Amyloid-Positive Patients With Mild Cognitive Impairment or Mild DementiaPieter J van der Veere, Jeroen Hoogland, Leonie N C Visser, et al.
Alzheimer'S Research & Therapy|February 6, 2026
Real-world diagnostic performance of blood-based biomarkers for Alzheimer's disease: robust performance except after stroke and high charlson comorbidity indexSinthujah Vigneswaran, Inge M W Verberk, Rebecca Z Rousset, et al.
Differentiation; Research in Biological Diversity|December 9, 2016
Loss of Rearranged L-Myc Fusion (RLF) results in defects in heart development in the mouseL M Bourke, G Del Monte-Nieto, J E Outhwaite, et al.
Cancers|August 27, 2021
Preferences of Treatment Strategies among Women with Low-Risk DCIS and OncologistsDanalyn Byng, Valesca P Retèl, Ellen G Engelhardt, et al.
JAMA Network Open|July 10, 2025
Cerebrospinal Fluid Amyloid and Tau Biomarker Changes Across the Alzheimer Disease Clinical SpectrumDiederick M de Leeuw, Calvin Trieu, Ellen M Vromen, et al.
Journal for Immunotherapy of Cancer|March 26, 2024
Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trialRenske M T Ten Ham, Maartje W Rohaan, Inge Jedema, et al.
Pageof 87